Tamer Mahmoud Abdelfattah Mohamed

Tamer Mahmoud Abdelfattah Mohamed, PhD

Picture

Tamer Mahmoud Abdelfattah Mohamed, PhD

Associate Professor / Director of the Center for Cardiac Engineering and Regenerative Therapeutics (CERT)

Email

u251513@bcm.edu

Positions

Associate Professor / Director of the Center for Cardiac Engineering and Regenerative Therapeutics (CERT): Division of Cardiothoracic Surgery
Baylor College of Medicine

Associate Professor: Medicine
University of Louisville
Louisville, Kentucky United States

Scientist II: Gene Therapy
Tenaya Therapeutics
San Francisco, California United States

Addresses

McNair Campus (MCHP) (Lab)
: Room: MCHP-A06.182
Houston, TX 77030
United States

McNair Campus (MCHP) (Office)
: Room: MCHP-A06.182
Houston, TX 77030
United States

Education

Postdoctoral Training at Gladstone Institute: 10/2017 - San Francisco, California United States

PhD from University of Manchester: 05/2008 - Manchester, United Kingdom

MSc from Zagazig University: 03/2003 - Zagazig

PharmD from Zagazig University: 05/1999 - Zagazig, Egypt

Professional Interests

Professional Statement

Tamer M. Mohamed, Ph.D., M.Sc., has broad expertise in molecular cardiology and drug screening in addition to cardiac regeneration and epigenetics. During his research endeavors, he studied novel mechanisms and therapies for cardiac hypertrophy and heart failure.

His research had a major impact on two approaches for endogenous heart repair: direct cardiac reprogramming and inducing cardiomyocyte proliferation. Both approaches were highly successful.

The direct reprogramming approach was the nucleus for an emerging start-up (Tenaya Therapeutics) where he was the first scientist recruited to the company to lead the efforts of direct cardiac reprogramming.

Due to the quick success of Tenaya, which IPO in August 2021 to start clinical trials, the research and development section ended very soon and now the major focus is on scaling up viral manufacturing and filing IND which is away from his interest. Therefore, he decided to go back to academia to initiate new discovery programs for heart failure therapy mainly focusing on understanding the regulation of cardiomyocyte proliferation (Abouleisa et al., Circulation, 2022, and Mohamed et al., Cell, 2018).

Most recently, his laboratory established a novel system for long-term culture of human and pig heart slices and efficiently demonstrated the efficacy of new cardiac regenerative therapies in such pre-clinical models (Ou et al., Circulation Research, 2019). This technology has opened a new avenue of research to explore pathophysiological mechanisms and toxicities in primary pig and human heart tissues.